Clinical Trials List
2023-12-01 - 2027-03-31
Phase II
Not yet recruiting3
Recruiting3
ICD-10C78.5
Secondary malignant neoplasm of large intestine and rectum
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9197.5
Secondary malignant neoplasm of large intestine and rectum
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 林宗哲 無
- 梁逸歆 無
- 陳國興 無
- Ying-Chun Shen 無
- 張端瑩 無
- JHE-CYUAN GUO 無
- YU-YUN SHAO 無
- Chiun Hsu 無
- TA-CHEN HUANG 無
- 呂理駿 無
- Chih-Hung Hsu 無
- 郭弘揚 無
- Ann-Lii Cheng 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Po-Wen Lin 無
- 黃盈慈 無
- 陳柏全 無
- 黃怡璇 無
- Peng-Chan Lin 無
- 詹仁豪 無
- Shang-Hung Chen 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 張境夫 無
- 賴盈傑 無
- Jen-Shi Chen 無
- 呂嘉偉 無
- 黃振洋 無
- Yung-Chia Kao 無
- Chia-Hsun Hsieh 無
- Tsai-Sheng Yang 無
- 余紹銘 無
- 黃文冠 無
- Wen-Chi Chou 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張琮琨 無
- 蔡祥麟 無
- Yen-Cheng Chen 無
- 黃敬文 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
280 participants
